Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ellis

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
RSC Medicinal Chemistry|August 6, 2021
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitorsAnmol Gulati, Charles S Yeung, Blair Lapointe, et al.
Science Translational Medicine|April 24, 2020
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficitsMarco A S Baptista, Kalpana Merchant, Ted Barrett, et al.
Journal of Medicinal Chemistry|December 8, 2022
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1<i>H</i>-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's DiseaseDavid A Candito, Vladimir Simov, Anmol Gulati, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 20, 2006
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubtElias J Anaissie, Brahm H Segal, John R Graybill, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
RSC Medicinal Chemistry|August 6, 2021
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitorsAnmol Gulati, Charles S Yeung, Blair Lapointe, et al.
Science Translational Medicine|April 24, 2020
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficitsMarco A S Baptista, Kalpana Merchant, Ted Barrett, et al.
Journal of Medicinal Chemistry|December 8, 2022
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1<i>H</i>-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's DiseaseDavid A Candito, Vladimir Simov, Anmol Gulati, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 20, 2006
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubtElias J Anaissie, Brahm H Segal, John R Graybill, et al.
Pageof 13